DK1349846T3 - Arylerede furan- og thiohencarboxylsyreamider med kaliumkanalblokerende virkning - Google Patents

Arylerede furan- og thiohencarboxylsyreamider med kaliumkanalblokerende virkning

Info

Publication number
DK1349846T3
DK1349846T3 DK01985832T DK01985832T DK1349846T3 DK 1349846 T3 DK1349846 T3 DK 1349846T3 DK 01985832 T DK01985832 T DK 01985832T DK 01985832 T DK01985832 T DK 01985832T DK 1349846 T3 DK1349846 T3 DK 1349846T3
Authority
DK
Denmark
Prior art keywords
thiohene
carboxylic acid
acid amides
potassium channel
blocking effect
Prior art date
Application number
DK01985832T
Other languages
Danish (da)
English (en)
Inventor
Stefan Peukert
Joachim Brendel
Horst Hemmerle
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK1349846T3 publication Critical patent/DK1349846T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01985832T 2000-12-12 2001-11-29 Arylerede furan- og thiohencarboxylsyreamider med kaliumkanalblokerende virkning DK1349846T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10061876A DE10061876A1 (de) 2000-12-12 2000-12-12 Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2001/013958 WO2002048131A1 (de) 2000-12-12 2001-11-29 Arylierte furan- und thiophencarbonsäureamide mit kalium kanal blockierender wirkung

Publications (1)

Publication Number Publication Date
DK1349846T3 true DK1349846T3 (da) 2005-05-30

Family

ID=7666837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01985832T DK1349846T3 (da) 2000-12-12 2001-11-29 Arylerede furan- og thiohencarboxylsyreamider med kaliumkanalblokerende virkning

Country Status (30)

Country Link
US (1) US6982279B2 (ru)
EP (1) EP1349846B1 (ru)
JP (1) JP4252798B2 (ru)
KR (1) KR20030061846A (ru)
CN (1) CN1225463C (ru)
AR (1) AR032781A1 (ru)
AT (1) ATE288906T1 (ru)
AU (2) AU3574302A (ru)
BR (1) BR0116084A (ru)
CA (1) CA2431095A1 (ru)
CZ (1) CZ20031633A3 (ru)
DE (2) DE10061876A1 (ru)
DK (1) DK1349846T3 (ru)
EE (1) EE05306B1 (ru)
ES (1) ES2236335T3 (ru)
HK (1) HK1061850A1 (ru)
HR (1) HRP20030469A2 (ru)
HU (1) HUP0303665A3 (ru)
IL (2) IL156314A0 (ru)
MX (1) MXPA03004770A (ru)
NO (1) NO329163B1 (ru)
NZ (1) NZ526383A (ru)
PL (1) PL362410A1 (ru)
PT (1) PT1349846E (ru)
RS (1) RS50336B (ru)
RU (1) RU2275366C2 (ru)
SK (1) SK287464B6 (ru)
TW (1) TWI288134B (ru)
WO (1) WO2002048131A1 (ru)
ZA (1) ZA200304091B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
CN100413861C (zh) * 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
KR20080016597A (ko) * 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
WO2007124849A2 (en) * 2006-04-27 2007-11-08 Sanofi-Aventis Deutschland Gmbh Inhibitors of the task-1 and task-3 ion channel
EP2559692A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
MX2010002712A (es) * 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
ITMI20071971A1 (it) * 2007-10-10 2009-04-11 Altergon Sa Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2400964A4 (en) * 2009-01-30 2012-08-01 Glaxosmithkline Llc CRYSTALLINE FORM OF N - {(1-5) -2-AMINO-1 - [(3-FLUOROPHENYL) METHYL] ETHYL} -5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PYRAZOL) CHLOROHYDRATE 5-YL) -2-THIOPHENE CARBOXAMIDE
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス，エルエルシーＮｏｖｏｍｅｄｉｘ，Ｌｌｃ フラニル化合物およびその使用
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (ru) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
KR101721490B1 (ko) * 2014-07-30 2017-03-30 한국생명공학연구원 페닐 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 세포증식성 질병의 예방 또는 치료용 약학적 조성물
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6013664A (en) * 1996-11-27 2000-01-11 Bayer Aktiengesellschaft Microbicidal agents based on thiophene-2-carboxylic acid derivatives
WO1999007670A1 (en) * 1997-08-05 1999-02-18 American Home Products Corporation Anthranilic acid analogs
JP3811006B2 (ja) * 1997-12-19 2006-08-16 シエーリング アクチエンゲゼルシャフト 抗凝血物質類としてのオルト−アントラニルアミド誘導体類
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
WO1999041231A1 (fr) * 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Derives amidino utilises comme ingredients actifs et medicaments les contenant
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
WO2000012077A1 (en) 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
WO2000075129A1 (en) * 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
EP1419161A1 (en) * 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease

Also Published As

Publication number Publication date
PL362410A1 (en) 2004-11-02
DE50105337D1 (de) 2005-03-17
ZA200304091B (en) 2004-04-23
EE200300240A (et) 2003-08-15
US20040068120A1 (en) 2004-04-08
IL156314A0 (en) 2004-01-04
JP4252798B2 (ja) 2009-04-08
NO20032535D0 (no) 2003-06-04
HK1061850A1 (en) 2004-10-08
CZ20031633A3 (cs) 2003-08-13
JP2004526680A (ja) 2004-09-02
CA2431095A1 (en) 2002-06-20
CN1225463C (zh) 2005-11-02
EE05306B1 (et) 2010-06-15
HRP20030469A2 (en) 2005-04-30
US6982279B2 (en) 2006-01-03
ES2236335T3 (es) 2005-07-16
HUP0303665A3 (en) 2005-02-28
DE10061876A1 (de) 2002-06-20
AR032781A1 (es) 2003-11-26
PT1349846E (pt) 2005-05-31
NO20032535L (no) 2003-07-29
BR0116084A (pt) 2003-10-14
HUP0303665A2 (hu) 2004-03-01
EP1349846A1 (de) 2003-10-08
TWI288134B (en) 2007-10-11
NZ526383A (en) 2004-11-26
AU3574302A (en) 2002-06-24
CN1479734A (zh) 2004-03-03
NO329163B1 (no) 2010-08-30
MXPA03004770A (es) 2003-09-10
KR20030061846A (ko) 2003-07-22
SK287464B6 (sk) 2010-10-07
ATE288906T1 (de) 2005-02-15
RU2275366C2 (ru) 2006-04-27
YU42503A (sh) 2006-05-25
RS50336B (sr) 2009-11-10
AU2002235743B2 (en) 2006-07-20
IL156314A (en) 2008-12-29
EP1349846B1 (de) 2005-02-09
WO2002048131A1 (de) 2002-06-20
SK7252003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
DK1349846T3 (da) Arylerede furan- og thiohencarboxylsyreamider med kaliumkanalblokerende virkning
AU2002235743A1 (en) Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect
DE60141247D1 (de) Bandkassette und bandeinheit
DE60124035D1 (de) Aufzeichnungsgerät und Aufzeichnungsverfahren
NO20025872L (no) Forbindelse med koniske gjenger
DE60139763D1 (de) Lanzen und -tieren
DE60131797D1 (de) Spielsystem und entsprechendes computerlesbares Aufzeichungsmedium
DE60143685D1 (de) Fördergerät und Aufzeichnungsgerät
ATE297920T1 (de) Linezolid-krystall form ii
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
DE60105565D1 (de) Stabiles und wirksames weiches feststoffprodukt
DE60107990D1 (de) Foliebehandlungsvorrichtung und Umwickelvorrichtung
DE60140478D1 (de) Malonamid- und malonsäureamid-ester-derivate mit aerwendung
DE60144553D1 (de) Tuner und Abstimmgerät
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
NO20014184L (no) Magnetisk kjerne med en effektiv formagnetisering og magnetisk anordning medanvendelse av kjernen
DE60121845D1 (de) Spielsystem und entsprechendes computerlesbares Aufzeichungsmedium
EP1350090A4 (en) COMBINED OXYGEN AND NOx SENSOR
DE50112183D1 (de) Walzenvorrichtung
SI1349846T1 (en) Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect
DE10195416T1 (de) Plattenaufzeichnungs- und/oder Wiedergabegerät
FR2807383B1 (fr) Frein de bicyclette et bicyclette equipee de ce frein
DE29901668U1 (de) Schal und Krawatte
FR2805558B1 (fr) Ecran solaire et coupe-vent portable
DE60126285D1 (de) Härtbare zusammensetzung und deren verwendungen